$PBLA
Panbela Therapeutics, Inc.

2022 Q3 Form 10-Q Financial Statement

#000143774922020539 Filed on August 15, 2022

View on sec.gov

Income Statement

Concept 2022 Q3 2022 Q2 2022 Q1
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $1.294M $1.258M $1.796M
YoY Change 40.04% -47.41% 56.17%
% of Gross Profit
Research & Development $2.329M $20.03M $2.208M
YoY Change 81.1% 1933.3% 100.91%
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $2.329M $20.03M $2.208M
YoY Change 81.1% 1933.3% 100.91%
Operating Profit -$3.623M -$21.29M -$4.004M
YoY Change 63.94% 856.24% 78.11%
Interest Expense $87.00K $16.00K $3.000K
YoY Change 4250.0% 300.0% 0.0%
% of Operating Profit
Other Income/Expense, Net -$835.0K -$862.0K $309.0K
YoY Change 148.51% 467.11% -347.2%
Pretax Income -$4.458M -$22.15M -$3.695M
YoY Change 75.1% 831.37% 55.71%
Income Tax -$56.00K -$18.00K -$29.00K
% Of Pretax Income
Net Earnings -$4.402M -$22.13M -$3.666M
YoY Change 105.51% 912.35% 62.43%
Net Earnings / Revenue
Basic Earnings Per Share -$0.21 -$1.51 -$0.27
Diluted Earnings Per Share -$211.8K -$1.510M -$272.7K
COMMON SHARES
Basic Shares Outstanding 20.77M 14.65M 13.45M
Diluted Shares Outstanding

Balance Sheet

Concept 2022 Q3 2022 Q2 2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $941.0K $2.530M $7.386M
YoY Change -93.31% -60.5% -8.81%
Cash & Equivalents $900.0K $2.500M $7.400M
Short-Term Investments
Other Short-Term Assets $779.0K $567.0K $182.0K
YoY Change 560.17% 170.0% -41.29%
Inventory
Prepaid Expenses $779.0K $567.0K $182.0K
Receivables
Other Receivables
Total Short-Term Assets $1.766M $3.456M $7.933M
YoY Change -88.03% -52.27% -10.25%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $3.101M $3.101M $3.155M
YoY Change 5750.94% 5538.18% 5636.36%
Total Long-Term Assets $3.101M $3.101M $3.155M
YoY Change 5750.94% 5538.18% 5636.36%
TOTAL ASSETS
Total Short-Term Assets $1.766M $3.456M $7.933M
Total Long-Term Assets $3.101M $3.101M $3.155M
Total Assets $4.867M $6.557M $11.09M
YoY Change -67.12% -10.12% 24.67%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $5.394M $3.211M $3.986M
YoY Change 577.64% 311.14% 409.72%
Accrued Expenses $758.0K $1.274M $521.0K
YoY Change 39.59% 108.17% -1.33%
Deferred Revenue
YoY Change
Short-Term Debt $650.0K $650.0K $0.00
YoY Change
Long-Term Debt Due $1.000M $1.000M
YoY Change
Total Short-Term Liabilities $7.952M $6.201M $4.507M
YoY Change 493.88% 345.15% 244.05%
LONG-TERM LIABILITIES
Long-Term Debt $5.194M $5.194M $0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $5.194M $5.194M $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $7.952M $6.201M $4.507M
Total Long-Term Liabilities $5.194M $5.194M $0.00
Total Liabilities $13.15M $11.40M $4.507M
YoY Change 881.78% 718.02% 244.05%
SHAREHOLDERS EQUITY
Retained Earnings -$86.40M -$82.00M -$59.80M
YoY Change 64.26% 62.38% 23.85%
Common Stock $21.00K $21.00K $13.00K
YoY Change 61.54% 110.0% 30.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$8.300M -$4.800M $6.581M
YoY Change
Total Liabilities & Shareholders Equity $4.867M $6.557M $11.09M
YoY Change -67.12% -10.12% 24.67%

Cashflow Statement

Concept 2022 Q3 2022 Q2 2022 Q1
OPERATING ACTIVITIES
Net Income -$4.402M -$22.13M -$3.666M
YoY Change 105.51% 912.35% 62.43%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities -$1.593M -$4.201M -$4.500M
YoY Change 14.94% 148.73% 129.01%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities -$1.000K -$655.0K
YoY Change
Cash From Investing Activities -$1.000K -$655.0K
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 5.000K 0.000 $0.00
YoY Change -99.94% -100.0% -100.0%
NET CHANGE
Cash From Operating Activities -1.593M -4.201M -$4.500M
Cash From Investing Activities -1.000K -655.0K
Cash From Financing Activities 5.000K 0.000 $0.00
Net Change In Cash -1.589M -4.856M -$4.481M
YoY Change -120.73% 187.85% 384.96%
FREE CASH FLOW
Cash From Operating Activities -$1.593M -$4.201M -$4.500M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
13443722
dei Trading Symbol
TradingSymbol
PBLA
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
CY2022Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2022Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2022Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2021Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2021Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2022Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
20774045
CY2022Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
20774045
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
13443722
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2022-06-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-39468
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
88-2805017
dei Entity Address Address Line1
EntityAddressAddressLine1
712 Vista Blvd #305
dei Entity Address City Or Town
EntityAddressCityOrTown
Waconia
dei Entity Address State Or Province
EntityAddressStateOrProvince
MN
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
55387
dei City Area Code
CityAreaCode
952
dei Local Phone Number
LocalPhoneNumber
479-1196
dei Security12b Title
Security12bTitle
Common Stock, $0.001 par value
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2022Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
20774045
CY2022Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
2530000 usd
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
11867000 usd
CY2022Q2 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
567000 usd
CY2021Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
91000 usd
CY2022Q2 us-gaap Income Taxes Receivable
IncomeTaxesReceivable
359000 usd
CY2021Q4 us-gaap Income Taxes Receivable
IncomeTaxesReceivable
321000 usd
CY2022Q2 us-gaap Assets Current
AssetsCurrent
3456000 usd
CY2021Q4 us-gaap Assets Current
AssetsCurrent
12279000 usd
CY2022Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
3101000 usd
CY2021Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
593000 usd
CY2022Q2 us-gaap Assets
Assets
6557000 usd
CY2021Q4 us-gaap Assets
Assets
12872000 usd
CY2022Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
3211000 usd
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
640000 usd
CY2022Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1274000 usd
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
2020000 usd
CY2022Q2 us-gaap Interest Payable Current
InterestPayableCurrent
66000 usd
CY2021Q4 us-gaap Interest Payable Current
InterestPayableCurrent
0 usd
CY2022Q2 us-gaap Notes Payable Current
NotesPayableCurrent
650000 usd
CY2021Q4 us-gaap Notes Payable Current
NotesPayableCurrent
0 usd
CY2022Q2 us-gaap Other Long Term Debt Current
OtherLongTermDebtCurrent
1000000 usd
CY2021Q4 us-gaap Other Long Term Debt Current
OtherLongTermDebtCurrent
0 usd
CY2022Q2 us-gaap Liabilities Current
LiabilitiesCurrent
6201000 usd
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
2660000 usd
CY2022Q2 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
5194000 usd
CY2021Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
0 usd
CY2022Q2 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
5194000 usd
CY2021Q4 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
0 usd
CY2022Q2 us-gaap Liabilities
Liabilities
11395000 usd
CY2021Q4 us-gaap Liabilities
Liabilities
2660000 usd
CY2022Q2 us-gaap Preferred Stock Value
PreferredStockValue
0 usd
CY2021Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 usd
CY2022Q2 us-gaap Common Stock Value
CommonStockValue
21000 usd
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
13000 usd
CY2022Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
76451000 usd
CY2021Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
66227000 usd
CY2022Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-81957000 usd
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-56161000 usd
CY2022Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
647000 usd
CY2021Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
133000 usd
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
-4838000 usd
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
10212000 usd
CY2022Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
6557000 usd
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
12872000 usd
CY2022Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1258000 usd
CY2021Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1241000 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3053000 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2391000 usd
CY2022Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
20028000 usd
CY2021Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
985000 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
22236000 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2084000 usd
CY2022Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-21286000 usd
CY2021Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-2226000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-25289000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-4475000 usd
CY2022Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
2000 usd
CY2021Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
0 usd
us-gaap Investment Income Interest
InvestmentIncomeInterest
2000 usd
us-gaap Investment Income Interest
InvestmentIncomeInterest
0 usd
CY2022Q2 us-gaap Interest Expense
InterestExpense
16000 usd
CY2021Q2 us-gaap Interest Expense
InterestExpense
4000 usd
us-gaap Interest Expense
InterestExpense
20000 usd
us-gaap Interest Expense
InterestExpense
7000 usd
CY2022Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-848000 usd
CY2021Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-148000 usd
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-536000 usd
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-269000 usd
CY2022Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-862000 usd
CY2021Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-152000 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-554000 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-276000 usd
CY2022Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-22148000 usd
CY2021Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-2378000 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-25843000 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-4751000 usd
CY2022Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-18000 usd
CY2021Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-192000 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-47000 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-308000 usd
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-22130000 usd
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-2186000 usd
us-gaap Net Income Loss
NetIncomeLoss
-25796000 usd
us-gaap Net Income Loss
NetIncomeLoss
-4443000 usd
CY2022Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
813000 usd
CY2021Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
140000 usd
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
514000 usd
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
239000 usd
CY2022Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-21317000 usd
CY2021Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-2046000 usd
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-25282000 usd
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-4204000 usd
CY2022Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.51
CY2021Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.22
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.84
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.44
CY2022Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
14654102
CY2021Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
10092995
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
14049910
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
9989705
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
10212000 usd
CY2022Q1 us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
0 usd
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
334000 usd
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-3666000 usd
CY2022Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-299000 usd
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
6581000 usd
CY2022Q2 us-gaap Stock Issued During Period Value Acquisitions
StockIssuedDuringPeriodValueAcquisitions
9605000 usd
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
293000 usd
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-22130000 usd
CY2022Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
813000 usd
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
-4838000 usd
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
8448000 usd
CY2021Q1 pbla Stock Issued During Period Value Exercise Of Warrants For Cash
StockIssuedDuringPeriodValueExerciseOfWarrantsForCash
1042000 usd
CY2021Q1 pbla Stock Issued During Period Value Cashless Exercise Of Warrants
StockIssuedDuringPeriodValueCashlessExerciseOfWarrants
0 usd
CY2021Q1 us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
0 usd
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
252000 usd
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-2257000 usd
CY2021Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
99000 usd
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
7584000 usd
CY2021Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
364000 usd
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-2186000 usd
CY2021Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
140000 usd
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
5902000 usd
us-gaap Net Income Loss
NetIncomeLoss
-25796000 usd
us-gaap Net Income Loss
NetIncomeLoss
-4443000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
627000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
616000 usd
pbla Noncash Interest Expense
NoncashInterestExpense
13000 usd
pbla Noncash Interest Expense
NoncashInterestExpense
0 usd
us-gaap Increase Decrease In Income Taxes Receivable
IncreaseDecreaseInIncomeTaxesReceivable
33000 usd
us-gaap Increase Decrease In Income Taxes Receivable
IncreaseDecreaseInIncomeTaxesReceivable
251000 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
219000 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-130000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-3658000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-655000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
0 usd
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
0 usd
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
1042000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
0 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
1042000 usd
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
-2000 usd
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
-1000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-9337000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-2617000 usd
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
11867000 usd
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
9022000 usd
pbla Payments To Acquire Deposits Investing Activities
PaymentsToAcquireDepositsInvestingActivities
2561000 usd
pbla Payments To Acquire Deposits Investing Activities
PaymentsToAcquireDepositsInvestingActivities
-0 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
2483000 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
484000 usd
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-931000 usd
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-194000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-8680000 usd
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
2530000 usd
CY2021Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
6405000 usd
us-gaap Interest Paid Net
InterestPaidNet
7000 usd
us-gaap Interest Paid Net
InterestPaidNet
7000 usd
CY2022Q2 pbla Number Of Subsidiaries
NumberOfSubsidiaries
3 pure
us-gaap Nature Of Operations
NatureOfOperations
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><em style="font: inherit;">2.</em></b>         <b>Risks and Uncertainties</b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The Company operates in a highly regulated and competitive environment. The development, manufacturing and marketing of pharmaceutical products require approval from, and are subject to ongoing oversight by, the Food and Drug Administration (“FDA”) in the United States, the Therapeutic Goods Administration in Australia, the European Medicines Agency in the European Union, and comparable agencies in other countries. Obtaining approval for a new pharmaceutical product is never certain, <em style="font: inherit;"> may </em>take many years, and is normally expected to involve substantial expenditures.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">We have incurred losses of $82.0 million since our inception in <em style="font: inherit;">2011.</em> For the <em style="font: inherit;">six</em> months ended <em style="font: inherit;"> June 30, 2022, </em>we incurred a net loss of $25.8 million. Included in the net loss for the <em style="font: inherit;">six</em> months ended <em style="font: inherit;"> June 30, 2022 </em>was $17.7 million of in process research and development (“IPR&amp;D”) written off as research and development (“R&amp;D”) expense subsequent to the acquisition of CPP. We also incurred negative cash flows from operating activities of approximately $8.7 million for this period. As we continue to pursue development activities and seek commercialization of our lead assets, we expect to incur substantial losses, which are likely to generate negative net cash flows from operating activities. As of <em style="font: inherit;"> June 30, 2022, </em>we had cash of $2.5 million, negative working capital of $2.7 million (current assets less current liabilities), and stockholders’ deficit of $4.8 million. The Company’s principal sources of cash have historically included the issuance of equity securities and convertible debt. CPP’s principal sources of cash have historically also included issuance of equity securities, convertible debt and additionally development partners.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The accompanying condensed consolidated financial statements have been prepared assuming that we will continue as a going concern, which contemplates the realization of assets and liquidation of liabilities in the normal course of business. The condensed<b> </b>consolidated financial statements do <em style="font: inherit;">not</em> include any adjustments relating to the recoverability or classification of assets or the amounts of liabilities that might result from the outcome of these uncertainties. Our current independent registered public accounting firm included a paragraph emphasizing this going concern uncertainty in their audit report regarding our <em style="font: inherit;">2021</em> financial statements dated <em style="font: inherit;"> March 24, 2022. </em>Our ability to continue as a going concern, realize the carrying value of our assets and discharge our liabilities in the ordinary course of business is dependent upon a number of factors, including our ability to obtain additional financing, the success of our development efforts, our ability to obtain marketing approval for our ivospemin (SBP-<em style="font: inherit;">101</em>), eflornithine (CPP-<em style="font: inherit;">1X</em>) and eflornithine sachets (CPP-<em style="font: inherit;">1X</em>-S) product candidates in the United States, Australia, the European Union or other markets, and Flynpovi outside of North America and ultimately our ability to market and sell our product candidates. These factors, among others, raise substantial doubt about our ability to continue operations as a going concern. See Note <em style="font: inherit;">4</em> titled “Liquidity and Business Plan.”</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">In <em style="font: inherit;"> March </em>of <em style="font: inherit;">2020,</em> the World Health Organization declared the spread of a novel strain of coronavirus (“COVID-<em style="font: inherit;">19”</em>) a global pandemic. Early in the pandemic, federal, state and local governmental authorities took actions to combat the spread of COVID-<em style="font: inherit;">19,</em> including through issuances of “stay-at-home” directives and similar mandates for many individuals to substantially restrict daily activities and for many businesses to curtail or cease normal operations. These measures, while intended to protect human life, led to initially significantly reduced economic activity. Vaccines became available at the end of <em style="font: inherit;">2020.</em> Distribution in the United States accelerated during the <em style="font: inherit;">first</em> quarter of <em style="font: inherit;">2021</em> and then leveled off in the <em style="font: inherit;">second</em> quarter. In the fall of <em style="font: inherit;">2021,</em> infection rates increased in the United States and other parts of the world as the result of the Delta variant. In winter of <em style="font: inherit;">2021,</em> the Omicron variant caused another increase in infections. In the <em style="font: inherit;">second</em> quarter of <em style="font: inherit;">2022,</em> infection rates were decreasing. The development and uncertainty of the situation continues to preclude any prediction as to the ultimate impact of COVID-<em style="font: inherit;">19</em> on the Company’s business, financial condition, results of operations and cash flows, which will depend largely on future developments directly or indirectly relating to the duration and scope of the COVID-<em style="font: inherit;">19</em> outbreak in the United States, Australia, Europe and the rest of the world. During the spring of <em style="font: inherit;">2021,</em> the Company experienced a delay in the manufacturing of the active product substance, which is manufactured in India. There was also a delay in the final manufacturing steps which are completed in the United States, in part related to COVID-<em style="font: inherit;">19.</em> To date neither <em style="font: inherit;">one</em> of these delays have caused a disruption in supply for our clinical or preclinical testing. In <em style="font: inherit;"> January </em>of <em style="font: inherit;">2022,</em> the Company announced the opening of a global randomized clinical trial, which is expected to be conducted in the United States, Europe and Australia. While opening of clinical sites in the US and the rest of the world has been slower than originally anticipated, due in part to resource fatigue in the medical community, the Company does <em style="font: inherit;">not</em> expect any serious disruption to the conduct of this new clinical trial associated with COVID-<em style="font: inherit;">19.</em> The Company’s administrative operations have been decentralized since inception of the Company, so the Company experienced <em style="font: inherit;">no</em> administrative disruptions or additional costs due to the pandemic or related restrictions.</p>
CY2022Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-82000000.0 usd
us-gaap Net Income Loss
NetIncomeLoss
-25800000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-8700000 usd
CY2022Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
2500000 usd
CY2022Q2 pbla Working Capital
WorkingCapital
2700000 usd
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
-4800000 usd
us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 9pt;"><b><i>Use of estimates</i></b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The preparation of condensed consolidated financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amount of expenses during the reporting period. Actual results could differ from those estimates, particularly given the significant social and economic disruptions and uncertainties.</p>
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
9488451
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
7562992
CY2022Q2 pbla License Agreement Milestone Payments Achievement
LicenseAgreementMilestonePaymentsAchievement
90000 usd
CY2022Q2 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
11508227
CY2022Q2 pbla Shares Reserved For Issuance Weighted Average Exercise Price
SharesReservedForIssuanceWeightedAverageExercisePrice
4.56
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
627000 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
616000 usd
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
2463636
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
5.76
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
8821 usd
pbla Sharebased Compensation Arrangement By Sharebased Payment Award Number Of Shares Available For Grant Grants In Period
SharebasedCompensationArrangementBySharebasedPaymentAwardNumberOfSharesAvailableForGrantGrantsInPeriod
1596754
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
0.35
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
-0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
-0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
19500
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
14.07
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
4040890
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
3.62
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
624573 usd
CY2022Q2 us-gaap Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Outstanding Options
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
4040890
us-gaap Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Remaining Contractual Term2
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
P7Y1M24D
CY2022Q2 us-gaap Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Exercise Price Beginning Balance1
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
3.622
CY2022Q2 us-gaap Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Exercisable Options
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
3589307
us-gaap Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Exercisable Options Weighted Average Remaining Contractual Term2
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2
P6Y9M25D

Files In Submission

Name View Source Status
0001437749-22-020539-index-headers.html Edgar Link pending
0001437749-22-020539-index.html Edgar Link pending
0001437749-22-020539.txt Edgar Link pending
0001437749-22-020539-xbrl.zip Edgar Link pending
ex_410772.htm Edgar Link pending
ex_410773.htm Edgar Link pending
ex_410774.htm Edgar Link pending
ex_410775.htm Edgar Link pending
ex_411168.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
pbla-20220630.xsd Edgar Link pending
pbla20220630_10q.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
pbla-20220630_cal.xml Edgar Link unprocessable
pbla-20220630_lab.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
pbla-20220630_pre.xml Edgar Link unprocessable
pbla20220630_10q_htm.xml Edgar Link completed
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
pbla-20220630_def.xml Edgar Link unprocessable